Literature DB >> 2227349

Isolation of zidovudine resistant Escherichia coli from AIDS patients.

C S Lewin1, B Watt, R Paton, S G Amyes.   

Abstract

Zidovudine-resistant Escherichia coli were isolated from faecal samples from 6 out of 11 AIDS patients receiving zidovudine. Resistance appeared to be due to the loss of thymidine kinase activity which is required for the phosphorylation of zidovudine to its active form. No zidovudine resistant enterobacteria were isolated from 30 control faecal samples. Hence, clinically, there appeared to be a high correlation between the development of zidovudine-resistance in E. coli and exposure to zidovudine (chi 2: 11.77, P less than 0.001). However the development of zidovudine resistance does not appear to be associated with cross-resistance to other antimicrobial agents as the zidovudine-resistant E. coli did not display a high degree of resistance to other antibacterials.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2227349     DOI: 10.1111/j.1574-6968.1990.tb13967.x

Source DB:  PubMed          Journal:  FEMS Microbiol Lett        ISSN: 0378-1097            Impact factor:   2.742


  7 in total

1.  Zidovudine (AZT) has a bactericidal effect on enterobacteria and induces genetic modifications in resistant strains.

Authors:  A Doléans-Jordheim; E Bergeron; F Bereyziat; S Ben-Larbi; O Dumitrescu; M-A Mazoyer; F Morfin; C Dumontet; J Freney; L P Jordheim
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-04-15       Impact factor: 3.267

2.  In vitro activities of nucleoside analog antiviral agents against salmonellae.

Authors:  S J Sperber; E L Feibusch; A Damiani; M P Weinstein
Journal:  Antimicrob Agents Chemother       Date:  1993-01       Impact factor: 5.191

3.  Intracellular activity of zidovudine (3'-azido-3'-deoxythymidine, AZT) against Salmonella typhimurium in the macrophage cell line J774-2.

Authors:  J L Herrmann; P H Lagrange
Journal:  Antimicrob Agents Chemother       Date:  1992-05       Impact factor: 5.191

4.  Repurposing Zidovudine in combination with Tigecycline for treating carbapenem-resistant Enterobacteriaceae infections.

Authors:  S M S Ng; J S P Sioson; J M Yap; F M Ng; H S V Ching; J W P Teo; R Jureen; J Hill; C S B Chia
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2017-10-10       Impact factor: 3.267

5.  Validation of a High-Throughput Screening Assay for Identification of Adjunctive and Directly Acting Antimicrobials Targeting Carbapenem-Resistant Enterobacteriaceae.

Authors:  Kenneth P Smith; James E Kirby
Journal:  Assay Drug Dev Technol       Date:  2016-04-05       Impact factor: 1.738

6.  Altered Gut Microbiome under Antiretroviral Therapy: Impact of Efavirenz and Zidovudine.

Authors:  Shilpa Ray; Aswathy Narayanan; Christian G Giske; Ujjwal Neogi; Anders Sönnerborg; Piotr Nowak
Journal:  ACS Infect Dis       Date:  2020-12-21       Impact factor: 5.084

Review 7.  Nucleoside Analogues as Antibacterial Agents.

Authors:  Jessica M Thomson; Iain L Lamont
Journal:  Front Microbiol       Date:  2019-05-22       Impact factor: 5.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.